See today's BioWorld Science
To read the full story, subscribe or sign in.
Musculoskeletal

Series A financing at Rheumagen supports HLA gene-editing therapies for autoimmune diseases

Jan. 10, 2025
The financing will enable progression of RG-0401.
BioWorld Science Financings Musculoskeletal Gene therapy Series A